India  

"Dr Reddy"

Latest news and video coverage curated from trusted media outlets

0
shares
ShareTweetSavePostSend
 

Equity indices trade higher, pharma stocks rally [Video]

Equity indices trade higher, pharma stocks rally

Equity benchmark indices traded higher during early hours on Friday amid mixed cues from their Asian peers. At 10:15 am, the BSE S-P Sensex was up by 136 points or 0.35 per cent at 39,115 while the..

Credit: ANI     Duration: 01:24Published
Equity indices nudge lower on weak global cues, banking stocks dip [Video]

Equity indices nudge lower on weak global cues, banking stocks dip

Equity benchmark indices traded lower during early hours on Thursday on the back of weak global cues after the US Federal Reserve indicated the interest rate could stay close to zero for years. At..

Credit: ANI     Duration: 01:09Published
Closing bell: Equity indices in positive terrain, Dr Reddy's top gainer [Video]

Closing bell: Equity indices in positive terrain, Dr Reddy's top gainer

Equity benchmark indices traded higher in the afternoon session on September 16 while Asian stocks were flat ahead of the US Federal Reserve's view on the economy. The BSE S-P Sensex closed 259 points..

Credit: ANI     Duration: 01:21Published
Russian Direct investment fund partners with Dr. Reddy's for Sputnik V trials in India|Oneindia News [Video]

Russian Direct investment fund partners with Dr. Reddy's for Sputnik V trials in India|Oneindia News

Dr Reddy's and the Russian Direct Investment Fund (RDIF) have agreed to conduct clinical trials and distribute 100 million doses of Russia's Sputnik V Covid-19 vaccine in India. The RDIF is Russia's..

Credit: Oneindia     Duration: 01:03Published
Equity indices spurt with rally in banking scrips, IndusInd up 12 pc [Video]

Equity indices spurt with rally in banking scrips, IndusInd up 12 pc

Equity benchmark indices traded higher on the first day of September futures and options series with banking and financials contributing significantly to the gains. The BSE S and P Sensex closed 354..

Credit: ANI     Duration: 01:13Published
Equity indices dip on weak global cues, pharma stocks hit [Video]

Equity indices dip on weak global cues, pharma stocks hit

Equity benchmark indices drifted lower during early hours on Wednesday amid weak global cues with pharma stocks losing the most. At 10:15 am, the BSE SandP Sensex was down by 181 points or 0.47 per..

Credit: ANI     Duration: 01:11Published
Equity indices close in the green, Cipla gains 9.5 pc [Video]

Equity indices close in the green, Cipla gains 9.5 pc

Equity benchmark indices shaved off early gains but ended in the positive terrain on Monday with pharma stocks leading the rally. At the closing bell, the BSE SandP Sensex was up by 142 points or 0.37..

Credit: ANI     Duration: 01:17Published
Equity indices gain 1% on global cues, metal stocks shine [Video]

Equity indices gain 1% on global cues, metal stocks shine

Equity benchmark indices were on upswing during early hours on August 05 amid positive global cues with metal and banking stocks leading the rally. At 10:15 am, the BSE SandP Sensex was up by 408..

Credit: ANI     Duration: 01:04Published

You Might Like


DRL launches generic of Precedex

Dr. Reddy’s has unveiled Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Hospira’s Preced
Hindu - Published

Mitesh Thakkar: BUY TCS, Dr Reddy’s; SELL Axis Bank and BPCL


TopNews - Published

India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks

Indian trials of the Sputnik-V vaccine candidate, being developed by Russia`s sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals..
DNA - Published Also reported by •IndiaTimes

The Hindu Explains | What do we know about Russia’s COVID-19 vaccine candidate Sputnik V?

How will the tie-up with Dr. Reddy’s Laboratories help India?
Hindu - Published

Equity indices close lower on profit booking, Dr Reddy's up 10 pc


newKerala.com - Published

Dr Reddy’s shares extend rally; zoom over 10%

On the NSE, it zoomed 9.92% to close at ₹ 5,306.
Hindu - Published

DRL, Celgene settle Revlimid patent suit

Pharma major Dr. Reddy’s Laboratories and Celgene, a wholly owned subsidiary of Bristol Myers Squibb, have settled their litigation relating to patent
Hindu - Published

COVID-19 vaccine to be available in India by early 2021: Union Health Minister Harsh Vardhan

Meanwhile, Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of the world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds..
DNA - Published

COVID-19 vaccination to be available by 'start of next year': Harsh Vardhan

Union Health Minister Harsh Vardhan on Thursday said that the coronavirus vaccine will be made available in the country by the start of next year. The remarks come at a time when India is recording..
Mid-Day - Published

Russia, Dr Reddy’s tie up for Sputnik V trial

Russia’s sovereign wealth fund – Russian Direct Investment Fund (RDIF) — has partnered Hyderabad-based drug maker Dr Reddy’s Laboratories to cooperate on clinical trials and distribution of..
IndiaTimes - Published

Dr Reddy’s inks deal to distribute 100 mn doses of Sputnik V


Indian Express - Published

Russia inks pact to test, supply Sputnik V vaccine to India

Agreement with Dr. Reddy’s Laboratories doesn’t include its manufacture.
Hindu - Published

Russia confirms deal with Dr. Reddy's for COVID-19 vaccine 'Sputnik V' trials in India, to supply 100 million doses

Russia's sovereign wealth fund on Wednesday agreed to supply 100 million doses of world's first COVID-19 vaccine Sputnik-V to Indian drug company Dr Reddy's Laboratories as Moscow speeds up plans to..
DNA - Published

Russia to sell 100 million doses of Covid-19 vaccine to India

Russia's sovereign wealth fund said on Wednesday it will supply India's Dr Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against Covid-19 once it receives regulatory approval...
IndiaTimes - Published Also reported by •newKerala.comMid-Day

Equity indices in positive terrain, Dr Reddy's top gainer


newKerala.com - Published

DRL prices Remdesivir at ₹5,400 a vial

Dr. Reddy’s Laboratories has unveiled Gilead Sciences’ Remdesivir, an investigational drug used in COVID-19 treatment, under the Redyx brand in India
Hindu - Published

Dr Reddy's launches Remdesivir in India

Pharma major Dr Reddy’s Laboratories Ltd on Wednesday announced the rollout of potential Covid-19 treatment generic drug Remdesivir, under the Redyx brand name in India. Dr Reddy’s has announced..
IndiaTimes - Published Also reported by •Hindu

 Page 1  〉